These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3275064)

  • 21. Thalidomide in the treatment of graft-versus-host disease.
    Heney D; Bailey CC; Lewis IJ
    Biomed Pharmacother; 1990; 44(4):199-204. PubMed ID: 2204450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Thalidomide 1989].
    Codina C
    Med Clin (Barc); 1989 Apr; 92(15):571-2. PubMed ID: 2666770
    [No Abstract]   [Full Text] [Related]  

  • 23. Thalidomide--the need for a new clinical evaluation of an old drug.
    Ehninger G; Eger K; Stuhler A; Schuler U
    Bone Marrow Transplant; 1993; 12 Suppl 3():S26-8. PubMed ID: 8124253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of thalidomide in chronic refractory graft versus host disease.
    van de Poel MH; Pasman PC; Schouten HC
    Neth J Med; 2001 Aug; 59(2):45-9. PubMed ID: 11476911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extensive chronic graft-versus-host disease of skin successfully treated with thalidomide.
    Nair V; Sharma A; Ghosh I; Arora S; Sahai K; Dutta V
    J Assoc Physicians India; 2005 Nov; 53():988-90. PubMed ID: 16515241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
    Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of GVHD with cyclosporin A.
    Gratwohl A; Tichelli A; Nissen C; Stebler C; Speck B
    Bone Marrow Transplant; 1993; 12 Suppl 3():S32-5. PubMed ID: 8124255
    [No Abstract]   [Full Text] [Related]  

  • 29. Thalidomide for chronic GVHD.
    Sastry PS; Powles RL
    Bone Marrow Transplant; 1998 Nov; 22(9):933-4. PubMed ID: 9827827
    [No Abstract]   [Full Text] [Related]  

  • 30. Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A.
    Locatelli F; Uderzo C; Dini G; Zecca M; Arcese W; Messina C; Andolina M; Miniero R; Porta F; Rovelli A
    Bone Marrow Transplant; 1993 Dec; 12(6):627-33. PubMed ID: 8136746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study.
    Akpek G; Chinratanalab W; Lee LA; Torbenson M; Hallick JP; Anders V; Vogelsang GB
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):46-51. PubMed ID: 12533741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thalidomide for the therapy of graft-versus-host disease following allogeneic bone marrow transplantation.
    McCarthy DM; Kanfer EJ; Barrett AJ
    Biomed Pharmacother; 1989; 43(9):693-7. PubMed ID: 2696566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Perreault C; Gyger M; Boileau J; Bonny Y; Cousineau S; Lacombe M; Lavallee R; Tawil E; D'Angelo G
    Can Med Assoc J; 1983 Nov; 129(9):969-74. PubMed ID: 6367917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation.
    Eisner MD; August CS
    Bone Marrow Transplant; 1995 May; 15(5):663-8. PubMed ID: 7670393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients.
    Hägglund H; Boström L; Remberger M; Ljungman P; Nilsson B; Ringdén O
    Bone Marrow Transplant; 1995 Dec; 16(6):747-53. PubMed ID: 8750264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalidomide for graft-versus-host disease.
    McCarthy DM; Kanfer E; Taylor J; Barrett AJ
    Lancet; 1988 Nov; 2(8620):1135. PubMed ID: 2903342
    [No Abstract]   [Full Text] [Related]  

  • 38. Less acute GVHD in patients receiving totally matched transplants from unrelated donors.
    Lönnqvist B; Ljungman P; Norrby M; Olerup O; Ringdén O; Winiarski J
    Transplant Proc; 1995 Dec; 27(6):3528-9. PubMed ID: 8540084
    [No Abstract]   [Full Text] [Related]  

  • 39. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study.
    Scott MA; Gandhi MK; Jestice HK; Mahendra P; Bass G; Marcus RE
    Bone Marrow Transplant; 1998 Aug; 22(3):273-6. PubMed ID: 9720741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European Group or Blood and Marrow Transplantation (EBMT) Working Party on Late Effects.
    Tichelli A; Duell T; Weiss M; Socié G; Ljungman P; Cohen A; van Lint M; Gratwohl A; Kolb HJ
    Bone Marrow Transplant; 1996 Jun; 17(6):1105-11. PubMed ID: 8807122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.